Glycemic Index Laboratories, Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Los Angeles CA United States (2010)

Organization Overview

First Clinical Trial
2010
NCT00801814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

GI Labs | Glycemic Index Laboratories, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

polyglycoplex (2 trials)

Drugs in Phase 2 Trials (3)

high molecular weight oat beta-glucan (1 trial)

low molecular weight beta-glucan (1 trial)

medium molecular weight oat beta-glucan (1 trial)

Drugs in Phase 1 Trials (1)

met-2 (1 trial)

Drugs in Other Trials (3)

calcium propionate (1 trial)

fiber (1 trial)

sc-fos (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypercholesterolemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 8